Administration of gemcitabine and cisplatin in cancer patients with renal failure under hemodialysis
作者： Ping-Ying Chang , Ming-Shen Dai , Ching-Liang Ho , Nai-Shun Yao
DOI:
关键词:
摘要: Purpose There is no optimal dosing schedule of gemcitabine (GEM) and cisplatin (CDDP) combination for cancer patients with renal failure (RF) on hemodialysis (HD). The purpose this study was to share our experience using GEM CDDP in such patients. Methods starting dose defined based single-agent treatment two RF. Between November 2006 June 2009, 4 RF HD received a chemotherapy (CDDP 30mg/m(2) days 1, 8, 15 600mg/m(2) day 15; repeated every 28 days). conducted within 24 hours after the completion and/or administration. Results Reduced-dose showed efficacy good tolerability under HD.
jbuon.com参考文章(16)
H. L. Pearce, Anna Maria Storniolo, S. R B Allerheiligen, Preclinical, pharmacologic, and phase I studies of gemcitabine. Seminars in Oncology. ,vol. 24, ,(1997)
Alexander Kiani, Claus-Henning Köhne, Thorsten Franz, Jens Passauer, Thorsten Haufe, Peter Gross, Gerhard Ehninger, Eberhard Schleyer, Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment Cancer Chemotherapy and Pharmacology. ,vol. 51, pp. 266- 270 ,(2003) , 10.1007/S00280-003-0574-3
Alan P. Venook, Merrill J. Egorin, Gary L. Rosner, Donna Hollis, Sridhar Mani, Michael Hawkins, John Byrd, Raymond Hohl, Daniel Budman, Neal J. Meropol, Mark J. Ratain, Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565 Journal of Clinical Oncology. ,vol. 18, pp. 2780- 2787 ,(2000) , 10.1200/JCO.2000.18.14.2780
M. Matsuda, Gemcitabine for patients with chronic renal failure on hemodialysis Journal of Clinical Oncology. ,vol. 25, pp. 15189- 15189 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.15189
Ronald S. Go, Alex A. Adjei, Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin Journal of Clinical Oncology. ,vol. 17, pp. 409- 409 ,(1999) , 10.1200/JCO.1999.17.1.409
R Watanabe, Y Takiguchi, T Moriya, S Oda, K Kurosu, N Tanabe, K Tatsumi, K Nagao, T Kuriyama, Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer British Journal of Cancer. ,vol. 88, pp. 25- 30 ,(2003) , 10.1038/SJ.BJC.6600687
Masatoshi Tomita, Yoichi Aoki, Kenichi Tanaka, Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs Clinical Pharmacokinectics. ,vol. 43, pp. 515- 527 ,(2004) , 10.2165/00003088-200443080-00002
M.A. Zahra, A. Taylor, G. Mould, C. Coles, R. Crawford, L.T. Tan, Concurrent weekly cisplatin chemotherapy and radiotherapy in a haemodialysis patient with locally advanced cervix cancer. Clinical Oncology. ,vol. 20, pp. 6- 11 ,(2008) , 10.1016/J.CLON.2007.10.007
Raphael Gorodetsky, Akiva Vexler, Yaakov Bar-Khaim, Haim Biran, Plasma Platinum Elimination in a Hemodialysis Patient Treated with Cisplatin Therapeutic Drug Monitoring. ,vol. 17, pp. 203- 206 ,(1995) , 10.1097/00007691-199504000-00018
J.-L. Lagrange, E. Cassuto-Viguier, V. Barbé, J.-L. Fischel, J.-R. Mondain, M.-C. Etienne, J.-M. Ferréro, A. Creisson-Ducray, P. Formento, G. Milano, Cytotoxic effects of long-term circulating ultrafiltrable platinum species and limited efficacy of haemodialysis in clearing them European Journal of Cancer. ,vol. 30, pp. 2057- 2060 ,(1994) , 10.1016/0959-8049(94)00332-Y